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ABSTRACT: Teixobactin is a recently discovered antimicro-
bial cyclodepsipeptide with good activity against Gram positive
bacteria. Taking Arg10−teixobactin as a reference, where the
nonproteinogenic residue L-allo-enduracididine was substi-
tuted by arginine, a lysine scan was performed to identify the
importance of keeping the balance between hydrophilic and
hydrophobic amino acids for the antimicrobial activities of this
peptide family. Thus, the substitution of four isoleucine
residues present in the natural sequence by lysine led to a total
loss of activity. On the other hand, the substitution of the polar
noncharged residues and alanine by lysine allowed us to keep
and in some cases to improve the antimicrobial activity.
1. INTRODUCTION
Infectious diseases, including tuberculosis (TB), cause major
global health problems.1−5 This awareness accompanied by the
lobbying of some nongovernmental organizations has fueled
the renaissance of the search for new antibiotics.5 In this
scenario, the publication on teixobactin (1) (Figure 1) at the
beginning of 2015 by Ling et al. raised a pronounced
expectation.6 Teixobactin is a head to side-chain cyclo-
depsipeptide that exhibits good activity against Gram-positive
bacteria and TB.6−11 At the end of 2015, our group published
the first synthesis of an analogue of teixobactin, Arg10−
teixobactin (2) (Figure 1), where the nonproteinogenic amino
acid L-allo-enduracididine was substituted by arginine.7,12
Arg10−teixobactin (2) exhibits similar biological trends as
teixobactin (1) by showing better activity against Gram-positive
bacteria than against Gram-negative bacteria. However, Arg10−
teixobactin (2) was shown to be 1 order of magnitude less
active than the parent compound. In 2016, two groups, Payne
and co-workers and Li and co-workers,13,14 published the total
synthesis of the natural product (1).
At a glance, the structure of teixobactin, an 11 amino acid
peptide, can be defined as a scaffold formed by a linear segment
constituted with seven amino acid residues, which we named
tail, followed by a cyclic structure with four residues. In the
cycle, a D-Thr is at the bridgehead linked to an L-Ile, which
contains a guanidine side-chain amino acid, and the neutral
alanine completes the sequence. The tail end is an N-Me-D-Phe
and contains two more D-amino acids. Another characteristic
feature of this peptide is the presence in total of four isoleucine
and three polar uncharged residues (two serine and one
glutamine).
Although the structure of this peptide was known only
relatively recently, there are already a few reports on its
structure activity relationship. In this regard, our group and
Singh and co-workers independently found that the activity was
lost when the three D-amino acids in the tail were substituted
by the corresponding L-amino acids (phenylalanine, glutamine,
and isoleucine). This was also observed when the N-Me-D-Phe
at the N-terminal was substituted with N-Ac-D-Phe, indicating
the importance of a positive charge at the N-terminal.8,10
More recently and during the completion of this study,
Nowick and co-workers have reported another bioactivity
study, employing Arg10−teixobactin (2) as a reference.
15 The
main conclusions of their work are that the Lys10−teixobactin
(substitution of the arginine by lysine) is more active than (2).
Furthermore, the absolute stereochemistry is insignificant.
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Thus, the enantiomer, where L has been substituted by D
residues and vice versa, maintains the activity. Finally, the
residues 1−5 of the tail could be substituted by a dodecanoyl
group.
2. RESULTS AND DISCUSSION
In our current efforts to develop a more potent analogue of
teixobactin and later to explore the mode of action of this
family of compounds, a lysine scan was carried out. Lysine
scanning of a peptide involves the preparation of a set of
analogues, where each one contains a lysine residue in a
different position of the sequence while keeping the same
stereochemistry.16 In contrast to alanine scanning, which is a
more frequently used technique for the identification of amino
acids that are not key for biological activities, lysine scanning
has not been extensively reported in the literature for
antimicrobial peptides (AMPs).17,18
Lysine scanning could be extremely important to speed up
AMP medicinal chemistry programs because it may render
analogues with a better potency and is more easily modifiable
through the substitution of lysine by other basic residues.19
In this sense, eight analogues containing L-Lys at positions 2,
3, 6, 7, 9, and 11 and D-Lys at positions 4 and 5 were prepared.
Because D-Thr is essential for creating the ester bond and to
build up the depsipeptide cycle, the corresponding lysine
analogue at the bridgehead position 8 was not prepared. Also,
neither the analogue at position 1 (importance was previously
established by our group)10 nor the one at position 10
(reported by the group of Nowick and co-workers)15 was
investigated in this study. The eight lysine analogues covered
the substitution of the four hydrophobic isoleucine (repre-
sented by the red color in Figure 2), the three polar uncharged
residues 2× serine, glutamine(represented by the green color in
Figure 2), and the neutral alanine (represented by the yellow
color in Figure 2) by lysine.
Table 1 clearly shows that the substitution of four isoleucine
(three L- and one D-allo) by lysine led to a total loss of activity.
On the other hand, the substitution of the three polar
uncharged amino acids, (Ser3, Gln4, and Ser7) and the neutral
Ala9 maintained or improved the activity in some cases. Thus,
these data show that there is a relative balance between the
hydrophilic and hydrophobic parts in teixobactin analogues. As
shown in Table 1, introducing a polar positively charged
residue into the new analogues instead of a polar uncharged
residue improved the activity against some strains in
comparison with the reference Arg10−teixobactin (2). (For
example, Lys3−Arg10−teixobactin shows better activity against
the two bacterial strains Bacillus subtilis and Escherichia coli
than the reference Arg10−teixobactin. Also, it shows minimal
activity against Pseudomonas aeruginosa, whereas the reference
shows no activity against the same strains). Furthermore, Lys4−
Arg10−teixobactin and Lys9−Arg10−teixobactin exhibit activity
against Staphylococcus aureus and B. subtilis strains close to
Arg10−teixobactin and better activity against E. coli and P.
aeruginosa strains than the reference. This will facilitate the
possibility of finding analogues with improved activity by
substituting lysine by other basic residues such as arginine.
3. EXPERIMENTAL SECTION
3.1. Materials. All reagents and solvents were obtained
from commercial suppliers and used without further
Figure 1. Structure of teixobactin (1) and the Arg10−teixobactin analogue (2).
Figure 2. Illustration of lysine scanning on the Arg10−teixobactin
analogue.
Table 1. MIC (μg/mL) for Lys2−11 Teixobactin Analogues
MIC μg/mL (ATCC strains)
Gram (+) Gram (−)
entry S. aureus B. subtilis E. coli
P.
aeruginosa
Arg10−teixobactin (2)7 2 0.5 64 NI
Lys2 NI
a NI NI NI
Lys3 4 0.25 32 128
Lys4 4 1 32 128
Lys5 NI NI NI NI
Lys6 NI NI NI NI
Lys7 32 8 256 256
Lys9
b 6 1 50 100
Lys11 NI NI NI NI
meropenemc 0.0625 0.0625 0.03125 0.25
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purification. Analytical high-pressure liquid chromatography
(HPLC) was performed on an Agilent 1100 system, and the
Chemstation software was used for data processing. Buffer A
was 0.1% trifluoroacetic acid in H2O, and buffer B was 0.1%
trifluoroacetic acid in CH3CN. Liquid chromatography−mass
spectrometry (LC−MS) was performed on a Shimadzu 2020
ultrafiltration-LC−MS using an YMC-Triart C18 (5 μm, 4.6 ×
150 mm) column, and data processing was carried out using
the Lab Solution software. Buffer A was 0.1% formic acid in
H2O, and buffer B was 0.1% formic acid in CH3CN. Crude
peptides were purified with a Shimadzu LC-8A preparative
HPLC using a Phenomenex Luna C18(2) 100 Å column (10
μm × 250 mm). High-resolution mass spectrometry (HRMS)
was acquired using a Bruker ESI-Q-TOF mass spectrometer in
the positive mode. Matrix-assisted laser desorption ionization
(MALDI) was performed on a Bruker MALDI-TOF Autoflex
SmartBeam II system (Bruker Daltonics, Bremen, Germany)
using the MALDI matrix (α-cyano-4-hydroxycinnamic acid).
3.2. Methods. The eight analogues were synthesized using
the solid-phase peptide synthesis (SPPS) technique as
previously described.7,10 Succinctly, the synthesis was started
by anchoring a residue at position 9 [Fmoc-Ala-OH or Fmoc-
Lys(Boc)-OH in the case of the Lys9 analogue] to a chlorotrityl
chloride polystyrene resin (CTC-resin), and then the
elongation of the peptide chain was achieved by the use of
Fmoc-amino acids until residue at position 6 (isoleucine or
lysine in the case of the Lys6 analogue, in all cases except in the
synthesis where Lys11 analogue). Then, the β-hydroxyl
functional group of D-Thr, which had been incorporated
without protection, was acylated by Alloc-L-Ile-OH, followed by
the incorporation of Alloc-Arg(Pbf)-OH. Finally, the Fmoc-
based synthesis was continued until the incorporation of Boc-
N-Me-D-Phe-OH, whereas in the synthesis of the analogue
Lys11, the Fmoc-SPPS was performed until the incorporation of
Boc-N-Me-D-Phe-OH, and then the esterification of the
threonine amino acid was carried out by Fmoc-Lys(Boc)-OH
followed by the incorporation of Fmoc-Arg(Pbf)-OH.
The cleavage of the semiprotected peptide, having the free α-
amino acid group of arginine and the carboxylic group of
alanine or lysine in the case of the Lys9 analogue, was carried
out with 0.1% trifluoroacetic acid (TFA) in dichloromethane
followed by cyclization using ((7-azabenzotriazol-1-yloxy)-
tripyrrolidinophosphonium hexafluorophosphate/ethyl cyano-
(hydroxyimino)acetate/diisopropylethylamine, 3:3:6). The
final global deprotection was enabled with TFA/triisopropylsi-
lane/H2O (95:2.5:2.5), and the peptides were purified using
HPLC and characterized using HRMS (see the Supporting
Information). The minimum inhibitory concentration (MIC)
was determined as previously described, with meropenem as
the control (see the Supporting Information).10
4. CONCLUSIONS
In conclusion, performing a lysine scan has allowed the
identification of the essential residues for maintaining the
balance between the hydrophilic and hydrophobic amino acids
for the antimicrobial activity of teixobactin analogues. Thus, the
substitution of any of the isoleucine residues by lysine rendered
the compound with a total loss of activity. Furthermore, the
substitution of the three polar uncharged amino acids and
alanine by lysine allowed us to sustain the antimicrobial
potency and in some cases to improve it. We envisage that the
lysine scanning will become a useful tool for the discovery of
new AMPs as it has been shown in this study.
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